Abstract:Background: The Pharmacokinetics of Methotrexate (MTX) has been reported to show significant inter-subject variability. MTX is metabolized by SHMT1 and transported by OATP1B1 and OATP1B3 both of which show genetic polymorphisms. The non-genetic and genetic factors may influence the pharmacokinetics of MTX. Objective: This study aimed to determine the pharmacokinetic parameters of MTX in Chinese patients and to investigate the effect of various non-genetic factors and genetic variants of OATP1B1, OATP1B3 on MTX's pharmacokinetics. Methods: MTX concentration and clinical characteristics data were collected from 71 rheumatoid arthritis patients. For each patient, SLC19A1, SHMT1, OATP1B1, and OATP1B3 genotyping were tested. Population pharmacokinetic analysis was performed by Nonlinear Mixed-Effect Modeling (NONMEM). MTX pharmacokinetic properties analysis was executed using the one-compartment pharmacokinetic model which incorporated first-order conditional estimation methods with interaction. Besides, the impact of genetic factors and demographic factors on MTX disposition were explored. Results: All the genotypes of steady-state plasma concentrations and OATP1B1 rs4149056, OATP1B1 rs2306283, and OATP1B3 rs7311358 were determined. The detected blood drug concentration reached the standard. Genotypes were all measured. At the same time, the population pharmacokinetic model of methotrexate was obtained CL(L.h-1) =8.25x e0.167x SNP (SNP: SLCO1B1 388A/A=3; SLCO1B1 388A/G=2; SLCO1B1 388G/G=1); V(L)=32.8; Ka(h-1)= 1.69. Conclusion: In our study, it was showed that OATP1B1-388 G> A SNP had a significant effect on CL/F. The factor should be considered when determining MTX dosing. However, prospective studies with a large number of participants are needed to validate the results of this study.

Progress and Research in Pharmacogenetics of OATP1B1

Advances in investigations of gene polymorphisms and drug-drug interactions mediated by organic anion transporting polypeptides OATP1B1 and OATP1B3

Pharmacogenomics and Individualized Medication

Genetic Polymorphisms and Function of the Organic Anion-Transporting Polypeptide 1A2 and Its Clinical Relevance in Drug Disposition

Pharmacokinetics roles of organic anion transporting polypeptides

Genetic Polymorphisms of Human Hepatic OATPs: Functional Consequences and Effect on Drug Pharmacokinetics

[Effect of Genetic Polymorphism on the Activity of Drug Transporters and Its Clinical Significance].

Effect on drug transport of OATP1A2

Development of the Genetic Polymorphism Study on Organic Cation Transporters

Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients

Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium

Advances in Drug-drug Interactions Mediated by Organic Anion Trans-porting Polypeptides

[Personalized Dosing from Perspective of Pharmacogenomics of Drug Metabolizing Enzymes and Transporters].

The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions

Regulation of organic anion transporters: Role in physiology, pathophysiology, and drug elimination

Research status of organic anion transport polypeptide 1B1 in transcription and protein expression regulation mechanism

Progress of Pharmacogenomics and Individual Drug Design

The Relationship Between Main Transporter Pharmacogenetics and Statin Efficacy

Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking

The involvement of human organic anion transporting polypeptides (OATPs) in drug-herb/food interactions

Pharmacogenomics--genomics approaches to optimizing drug therapy